The S1PR3-driven oncogenic effects are mainly ascribed to the activation of ERK1/2 signaling pathways, which have been known as key regulatory mechanisms in the cell cycle progression, survival, and proliferation of breast cancer cells (Watson et al., 2010; Datta et al., 2014; Wang et al., 2016). Here, S1PR3 is linked to breast cancer.